The Challenges of Treating Patients with HCV Acquired From Injection Drug Use

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses some of the challenges in treating patients who acquired hepatitis C virus from injection drug use.


 

Achilles Alon: Those are particularly challenging. Their past with, you know, abusive drugs distracts them from being able to treat their HCV well. So, one of the biggest challenges is actually keeping a consistent communication path with them, and the reason why we need that communication path is to ensure that their taking their medications and are compliant, but we also have to make sure that we monitor for side effects and make sure that their going back to their doctor in order to get their blood tests to see if their viral is reducing.

If we don’t have that consistent communication path then things start to break down. So, I think patients that have had addiction problems in the past are also still dealing with that and are distracted with that, and sometimes it’s hard to keep that communication going.


 

Most Popular

Related Articles

Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
HIV infection is associated with higher rates of hepatitis C replication.
An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$